Caris Life Sciences reported a gross margin of 69.16% and a net margin of -0.24% for the quarter ended Jun 2026. These financial ratios cover 9 quarters of results from Jun 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross Margin | 40.60% | 46.06% | 56.94% | 49.64% | 63.99% | 69.11% | 76.39% | 66.28% | 69.16% |
| EBT Margin | -66.15% | -66.65% | -28.44% | -84.84% | -39.58% | 11.22% | 27.98% | -0.30% | -0.23% |
| EBIT Margin | -66.98% | -59.87% | -28.52% | -47.93% | -9.92% | 15.05% | 30.19% | 2.44% | 10.21% |
| EBITDA Margin | -66.98% | -59.87% | -28.52% | -47.93% | -9.92% | 15.05% | 30.19% | 2.44% | 10.21% |
| Operating Margin | -66.98% | -59.87% | -28.52% | -47.93% | -9.92% | 15.05% | 30.19% | 2.44% | 10.21% |
| Net Margin | -89.74% | -90.92% | -47.68% | -105.07% | -285.12% | 11.22% | 27.98% | -0.24% | -0.24% |
| FCF Margin | -70.12% | -31.72% | -28.14% | 3.25% | 25.52% | 13.55% | 10.42% | 2.43% | |
| Efficiency | |||||||||
| Inventory AverageInventory Avg. | 44.96M | 56.46M | 69.96M | 100.04M | |||||
| Assets AverageAssets Avg. | 969.81M | 1,055.12M | 1,144.03M | 1,196.00M | |||||
| Invested CapitalInvested Cap. | -2065.61M | 826.61M | 854.82M | 956.30M | 975.07M | 984.88M | |||
| Asset Utilization RatioAsset Util. | 0.67 | 0.77 | 0.79 | 0.83 | |||||
| Leverage & Solvency | |||||||||
| Interest Coverage RatioInterest Cover | -4.90 | -4.41 | -2.79 | -4.53 | -0.94 | 2.42 | 7.79 | 0.41 | 2.92 |
| Debt Ratio | 1.26 | 0.39 | 0.38 | 0.34 | 0.33 | 0.32 | |||
| Times Interest Earned | -4.90 | -4.41 | -2.79 | -4.53 | -0.94 | 2.42 | 7.79 | 0.41 | 2.92 |
| Valuation | |||||||||
| Price to EarningsP/E | -3.35 | 350.82 | 55.04 | -0.01M | -0.01M | ||||
| Price to SalesP/S | 9.56 | 39.36 | 15.40 | 23.38 | 19.10 | ||||
| Price to BookP/B | 3.83 | 17.84 | 7.81 | 8.52 | 8.51 | ||||
| Enterprise Value | 1,011.94M | 7,776.61M | 3,711.11M | 4,230.33M | 4,242.51M | ||||
| EV to EBIT | -56.25 | 238.24 | 41.98 | 800.90 | 157.56 | ||||
| EV to EBITDA | -56.25 | 238.24 | 41.98 | 800.90 | 157.56 | ||||
| Market Capitalization | 1,734.64M | 8,533.62M | 4,511.21M | 5,053.79M | 5,035.63M | ||||
| Price to FCFP/FCF | 293.91 | 154.23 | 113.66 | 224.27 | 786.57 | ||||
| EV to FCF | 171.46 | 140.55 | 93.50 | 187.73 | 662.69 | ||||
| EV to CFO | 138.85 | 124.58 | 82.87 | 128.68 | 148.98 | ||||
| Return Ratios | |||||||||
| Return on Sales [ROS]ROS | -66.98% | -59.87% | -28.52% | -47.93% | -9.92% | 15.05% | 30.19% | 2.44% | 10.21% |
| Return on Capital Employed [ROCE]ROCE | -9.09% | 4.86% | 10.83% | 15.26% | |||||
| Return on Invested Capital [ROIC]ROIC | 11.26% | 15.66% | |||||||
| Return on Assets [ROA]ROA | -19.28% | -6.45% | 2.97% | 8.79% |